Literature DB >> 2949587

Comparison of cardiodepressant and vasodilator effects of PN 200-110 (isradipine), nifedipine and diltiazem in anesthetized rabbits.

R P Hof.   

Abstract

Cardiodepressant and vasodilator effects of PN 200-110 (isradipine) were investigated in anesthetized open-chest rabbits and compared with those of nifedipine, diltiazem or placebo. In order to eliminate compensatory reflexes that may mask negative inotropic and chronotropic effects of blood pressure-lowering agents, the animals were vagotomized and pretreated with 1 mg/kg propranolol. Dose-response curves were obtained with 4 doses of each drug in 6 animals. The doses were chosen to cause comparable decreases in blood pressure. PN 200-110 had the highest efficacy with respect to peripheral vasodilatation (increase in total peripheral conductance) and coronary blood flow, measured with radioactive-labeled microspheres. It did not decrease myocardial contractile force (measured with a strain gauge). The 2 other compounds caused biphasic changes in coronary blood flow and cardiac output. Their efficacy with respect to peripheral vasodilatation was limited by cardiodepression. Their dose-response curve for cardiodepression was flat at the 2 smaller doses and became steeper at the 2 larger doses. Nifedipine did not change heart rate; PN 200-110 decreased it minimally and diltiazem had a dose-dependent negative chronotropic effect. After eliminating autonomic influences on the heart, direct myocardial effects of calcium antagonists become demonstrable in whole animals and can be compared with the vascular effects measured in the same animals.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2949587     DOI: 10.1016/0002-9149(87)90080-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Pharmacology of the calcium antagonist isradipine.

Authors:  U T Rüegg; R P Hof
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 2.  Isradipine in hypertension.

Authors:  L Hansson
Journal:  Drugs       Date:  1990       Impact factor: 9.546

3.  Multicentre isradipine dose-confirmation study in Thai patients with hypertension.

Authors:  S Tanomsup; P Tantbirojn; B Koanantakul; S Nontakanun; N Jaroonvesama; K Charoenlarp
Journal:  Drugs       Date:  1990       Impact factor: 9.546

4.  Different negative inotropic activity of Ca2(+)-antagonists in human myocardial tissue.

Authors:  R H Schwinger; M Böhm; E Erdmann
Journal:  Klin Wochenschr       Date:  1990-08-17

Review 5.  Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

Authors:  A Fitton; P Benfield
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

6.  Dose titration study of isradipine in Chinese patients with mild to moderate essential hypertension.

Authors:  M F Chen; C C Chen; W J Chen; C C Wu; C S Liau; Y T Lee
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

7.  Acute haemodynamic effects of isradipine in hypertensive heart transplant recipients.

Authors:  H Aass; S Simonsen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.